DaVita Can Return to Long-Term Volume Growth of 2% by 2029, UBS Says

MT Newswires Live07-10 22:58

DaVita (DVA) has a path back to 2% long-term volume growth by 2029, primarily driven by improving patient outcomes and reducing mortality rates, UBS analysts said in a Friday note.

Analysts said that DaVita has a wide range of levers, including the introduction of middle-molecule clearance technologies, increasing utilization of GLP-1s among existing dialysis patients, reducing missed treatment rates, and improving home care through DVA's investment in Elara Caring.

UBS said that there is increased focus on the company's Q2 volumes figure. Further improvements could suggest that modest improvements in mortality may indicate the start of a positive trend.

The company has yet to schedule a release date for its Q2 financial results.

Analysts retained a buy rating on the stock and increased its price target to $270 from $235.

Price: 232.55, Change: +3.07, Percent Change: +1.34

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2650913643?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-10 22:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650913643","market":"nz","top_or_hot":-1,"title":"DaVita Can Return to Long-Term Volume Growth of 2% by 2029, UBS Says","media":"MT Newswires Live","content":"<html><body><p> DaVita (DVA) has a path back to 2% long-term volume growth by 2029, primarily driven by improving patient outcomes and reducing mortality rates, UBS analysts said in a Friday note.</p><p>Analysts said that DaVita has a wide range of levers, including the introduction of middle-molecule clearance technologies, increasing utilization of GLP-1s among existing dialysis patients, reducing missed treatment rates, and improving home care through DVA's investment in Elara Caring.</p><p>UBS said that there is increased focus on the company's Q2 volumes figure. Further improvements could suggest that modest improvements in mortality may indicate the start of a positive trend.</p><p>The company has yet to schedule a release date for its Q2 financial results.</p><p>Analysts retained a buy rating on the stock and increased its price target to $270 from $235.</p><p>Price: 232.55, Change: +3.07, Percent Change: +1.34</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DaVita Can Return to Long-Term Volume Growth of 2% by 2029, UBS Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDaVita Can Return to Long-Term Volume Growth of 2% by 2029, UBS Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-10 22:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> DaVita (DVA) has a path back to 2% long-term volume growth by 2029, primarily driven by improving patient outcomes and reducing mortality rates, UBS analysts said in a Friday note.</p><p>Analysts said that DaVita has a wide range of levers, including the introduction of middle-molecule clearance technologies, increasing utilization of GLP-1s among existing dialysis patients, reducing missed treatment rates, and improving home care through DVA's investment in Elara Caring.</p><p>UBS said that there is increased focus on the company's Q2 volumes figure. Further improvements could suggest that modest improvements in mortality may indicate the start of a positive trend.</p><p>The company has yet to schedule a release date for its Q2 financial results.</p><p>Analysts retained a buy rating on the stock and increased its price target to $270 from $235.</p><p>Price: 232.55, Change: +3.07, Percent Change: +1.34</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2650913643","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2650913643","pubTimestamp":1783695530,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"DaVita  has a path back to 2% long-term volume growth by 2029, primarily driven by improving patient outcomes and reducing mortality rates, UBS analysts said in a Friday note.Analysts said that DaVita has a wide range of levers, including the introduction of middle-molecule clearance technologies, increasing utilization of GLP-1s among existing dialysis patients, reducing missed treatment rates, and improving home care through DVA's investment in Elara Caring.UBS said that there is increased focus on the company's Q2 volumes figure. Further improvements could suggest that modest improvements in mortality may indicate the start of a positive trend.The company has yet to schedule a release date for its Q2 financial results.Analysts retained a buy rating on the stock and increased its price target to $270 from $235.Price: 232.55, Change: +3.07, Percent Change: +1.34","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4196":"保健护理服务","BK4585":"ETF&股票定投概念","DVA":"达维塔保健","BK4559":"巴菲特持仓"},"translate_title":"瑞银表示，到 2029 年，DaVita 可以恢复 2% 的长期销量增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DVA":1},"content_text":"DaVita (DVA) has a path back to 2% long-term volume growth by 2029, primarily driven by improving patient outcomes and reducing mortality rates, UBS analysts said in a Friday note.Analysts said that DaVita has a wide range of levers, including the introduction of middle-molecule clearance technologies, increasing utilization of GLP-1s among existing dialysis patients, reducing missed treatment rates, and improving home care through DVA's investment in Elara Caring.UBS said that there is increased focus on the company's Q2 volumes figure. Further improvements could suggest that modest improvements in mortality may indicate the start of a positive trend.The company has yet to schedule a release date for its Q2 financial results.Analysts retained a buy rating on the stock and increased its price target to $270 from $235.Price: 232.55, Change: +3.07, Percent Change: +1.34","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2650913643","isCrawlerRequest":true}